Structure-based development of target-specific compound libraries.

The success or failure of a small-molecule drug discovery project ultimately lies in the choice of the scaffolds to be screened -- chosen from among the many millions of available compounds. Therefore, the methods used to design compound screening libraries are key for the development of new drugs that target a wide range of diseases. Currently, there is a trend towards the construction of receptor-structure-based focused libraries. Recent advances in high-throughput computational docking, NMR and crystallography have facilitated the development of these libraries. A structure-based target-specific library can save time and money by reducing the number of compounds to be experimentally tested, also improving the drug discovery success rate by identifying more-potent and specific binders.

[1]  Herbert Waldmann,et al.  Protein Structure Similarity as Guiding Principle for Combinatorial Library Design , 2003, Biological chemistry.

[2]  J Alper,et al.  Drug discovery on the assembly line. , 1994, Science.

[3]  T. Blundell,et al.  Structural biology and drug discovery. , 2005, Drug discovery today.

[4]  Yasuko Kato,et al.  Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism. , 2005, Journal of medicinal chemistry.

[5]  B. Shoichet,et al.  Soft docking and multiple receptor conformations in virtual screening. , 2004, Journal of medicinal chemistry.

[6]  A. Anderson.  The process of structure-based drug design. , 2003, Chemistry & biology.

[7]  Jordi Mestres,et al.  Exploring the active site of human factor Xa protein by NMR screening of small molecule probes. , 2003, Organic & biomolecular chemistry.

[8]  Ruben Abagyan,et al.  Derivation of sensitive discrimination potential for virtual ligand screening , 1999, RECOMB.

[9]  Roland E. Dolle.  Comprehensive Survey of Combinatorial Library Synthesis: 2003 , 2005 .

[10]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.

[11]  P. Hajduk,et al.  NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. , 1997, Journal of medicinal chemistry.

[12]  Clive McCarthy,et al.  Mapping the kinase domain of Janus Kinase 3. , 2003, Bioorganic & medicinal chemistry letters.

[13]  Gerhard Klebe,et al.  Virtual screening for inhibitors of human aldose reductase , 2004, Proteins.

[14]  Wolfgang Jahnke,et al.  Second-site NMR screening and linker design. , 2003, Current topics in medicinal chemistry.

[15]  Thomas Lengauer,et al.  FlexE: efficient molecular docking considering protein structure variations. , 2001, Journal of molecular biology.

[16]  Claudio N. Cavasotto,et al.  In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. , 2006, Bioorganic & medicinal chemistry letters.

[17]  Bert E Thomas,et al.  Quinic acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: design, synthesis, and crystal structure in complex with E-selectin. , 2005, Journal of medicinal chemistry.

[18]  Hugo O. Villar,et al.  Comments on the design of chemical libraries for screening , 2004, Molecular Diversity.

[19]  Johan Schultz,et al.  Site-selective screening by NMR spectroscopy with labeled amino acid pairs. , 2002, Journal of the American Chemical Society.

[20]  P. Hajduk,et al.  High-throughput nuclear magnetic resonance-based screening. , 1999, Journal of medicinal chemistry.

[21]  Roland E Dolle,et al.  Comprehensive survey of combinatorial library synthesis: 2003. , 2004, Journal of combinatorial chemistry.

[22]  Ian Tickle,et al.  High-throughput protein crystallography and drug discovery. , 2004, Chemical Society reviews.

[23]  Gang Liu,et al.  Potent, selective inhibitors of protein tyrosine phosphatase 1B. , 2003, Bioorganic & medicinal chemistry letters.

[24]  Silvia Schenone,et al.  Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives. , 2005, Journal of medicinal chemistry.

[25]  R. Kurumbail,et al.  Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors. , 2003, Journal of medicinal chemistry.

[26]  Robin Taylor,et al.  Comparing protein–ligand docking programs is difficult , 2005, Proteins.

[27]  Gerhard Klebe,et al.  Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.

[28]  Dan Fletcher,et al.  Determination of protein–ligand binding affinity by NMR: observations from serum albumin model systems , 2005, Magnetic resonance in chemistry : MRC.

[29]  Dustin J Maly,et al.  Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Hugo O Villar,et al.  Using NMR for ligand discovery and optimization. , 2004, Current opinion in chemical biology.

[31]  Gang Liu,et al.  Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. , 2003, Journal of medicinal chemistry.

[32]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[33]  Gerhard Klebe,et al.  Recent developments in structure-based drug design , 2000, Journal of Molecular Medicine.

[34]  Ernest Giralt,et al.  NMR-based methods and strategies for drug discovery. , 2003, Chemical Society reviews.

[35]  Claudio N. Cavasotto,et al.  Conformational Sampling of Protein Flexibility in Generalized Coordinates: Application to Ligand Docking , 2005 .

[36]  B. Shoichet,et al.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.

[37]  Gerard J Kleywegt,et al.  Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.

[38]  Tom L. Blundell,et al.  Keynote review: Structural biology and drug discovery , 2005 .

[39]  Finn Drabløs,et al.  Homology-based modelling of targets for rational drug design. , 2004, Mini reviews in medicinal chemistry.

[40]  Alexander D. MacKerell,et al.  Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. , 2004, Journal of medicinal chemistry.

[41]  H. Jhoti,et al.  The Discovery of Novel Protein Kinase Inhibitors by Using Fragment‐Based High‐Throughput X‐ray Crystallography , 2005, Chembiochem : a European journal of chemical biology.

[42]  H. Carlson.  Protein flexibility and drug design: how to hit a moving target. , 2002, Current opinion in chemical biology.

[43]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[44]  Brian K Shoichet,et al.  Testing a flexible-receptor docking algorithm in a model binding site. , 2004, Journal of molecular biology.

[45]  D. Sem,et al.  Object‐oriented approach to drug design enabled by NMR SOLVE: First real‐time structural tool for characterizing protein–ligand interactions , 2001, Journal of cellular biochemistry. Supplement.

[46]  Edward R Zartler,et al.  RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery. , 2003, Journal of the American Chemical Society.

[47]  Maurizio Pellecchia,et al.  Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. , 2004, Chemistry & biology.

[48]  Thierry Langer,et al.  Recent Advances in Docking and Scoring , 2005 .

[49]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[50]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[51]  Yan Guo,et al.  NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. , 2002, Journal of medicinal chemistry.

[52]  Thomas Peters,et al.  NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. , 2003, Angewandte Chemie.

[53]  Zhili Xin.  Potent, Selective Inhibitors of Protein Tyrosine Phosphatase 1B. , 2003 .

[54]  R. Dolle.  Comprehensive survey of combinatorial library synthesis: 2000. , 2001, Journal of combinatorial chemistry.

[55]  Johan Schultz,et al.  Site-selective labeling strategies for screening by NMR. , 2002, Combinatorial chemistry & high throughput screening.

[56]  Tom L Blundell,et al.  High-throughput X-ray crystallography for drug discovery. , 2004, Current opinion in pharmacology.

[57]  S. Homans.  NMR spectroscopy tools for structure-aided drug design. , 2004, Angewandte Chemie.

[58]  M. Totrov,et al.  A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. , 2004, Journal of medicinal chemistry.

[59]  Heather A Carlson,et al.  Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case. , 2004, Journal of the American Chemical Society.

[60]  Su-Ying Wu,et al.  Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. , 2003, Structure.

[61]  A. Sharff,et al.  High-throughput crystallography to enhance drug discovery. , 2003, Current opinion in chemical biology.

[62]  Claudio N. Cavasotto,et al.  The Challenge of Considering Receptor Flexibility in Ligand Docking and Virtual Screening , 2005 .

[63]  R. Kurumbail,et al.  Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. , 2003, Journal of medicinal chemistry.

[64]  Paul G Wyatt,et al.  Detection of ligands from a dynamic combinatorial library by X-ray crystallography. , 2003, Angewandte Chemie.

[65]  Thomas Lengauer,et al.  Structure Based Drug Design , 2005 .

[66]  Heather A Carlson,et al.  Protein flexibility is an important component of structure-based drug discovery. , 2002, Current pharmaceutical design.

[67]  R. Kurumbail,et al.  Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. , 2003, Bioorganic & medicinal chemistry letters.

[68]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[69]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[70]  Valler,et al.  Diversity screening versus focussed screening in drug discovery. , 2000, Drug discovery today.

[71]  Maurizio Pellecchia,et al.  Selective Incorporation of 19F‐Labeled Trp Side Chains for NMR‐Spectroscopy‐Based Ligand–Protein Interaction Studies , 2003, Chembiochem : a European journal of chemical biology.

[72]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[73]  R. Desimone,et al.  Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.

[74]  Martin Stahl,et al.  Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening. , 2003, Journal of medicinal chemistry.

[75]  Maurizio Pellecchia,et al.  Use of selective Trp side chain labeling to characterize protein-protein and protein-ligand interactions by NMR spectroscopy. , 2003, Journal of the American Chemical Society.

[76]  J. Mason,et al.  Diversity assessment. , 1999, Current opinion in chemical biology.

[77]  Leach,et al.  The in silico world of virtual libraries. , 2000, Drug discovery today.